Key result
Pre-treatment with blue mussel-α-chymotrypsin hydrolysate (BMCH) increased HUVEC viability, reduced ROS generation, and decreased H2O2-mediated apoptosis through inhibition of caspase-3 activation.
Why the study?
Enhanced oxidative stress plays a central role in promoting endothelial dysfunction leading to atherosclerosis, prompting investigation into whether blue mussel hydrolysates protect against oxidative injury in endothelial cells.
Blue mussel hydrolysate protects endothelial cells from oxidative stress-induced apoptosis in vitro, suggesting potential utility against endothelial dysfunction.
Hypothesis-generating for BMCH in endothelial protection; leaves open any role in human cardiovascular therapy.
Enhanced oxidative stress plays a central role in promoting endothelial dysfunction, leading to the development of atherosclerosis. In this study, we investigated the protective effects of the hydrolysates derived from blue mussel (Mytilus edulis) against H2O2-mediated oxidative injury in human umbilical vein endothelial cells (HUVECs). The blue mussel hydrolysates were prepared by enzymatic hydrolysis with eight proteases, and blue mussel-α-chymotrypsin hydrolysate (BMCH) showed the highest antioxidant activities in DPPH radical scavenging, ABTS+ radical scavenging, and ORAC value compared to those of the other hydrolysates. BMCH also inhibited Cu2+-mediated low density lipoprotein (LDL) oxidation. Treatment of H2O2 resulted in the decreased HUVEC viability whereas pre-treatment with BMCH increased HUVEC viability and reduced reactive oxygen species (ROS) generation. BMCH pre-treatment increased cellular antioxidant capacities, including levels of glutathione (GSH), superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) against H2O2-mediated oxidative stress in HUVECs. Flow cytometry and western blot analysis revealed that BMCH pre-treatment significantly reduced H2O2-mediated HUVEC apoptosis through inhibition of caspase-3 activation. Real-time-qPCR analysis showed that BMCH down-regulated expression of p53 and caspase-3 genes, as well as decreased the bax/bcl-2 ratio. Taken together, these results indicate that BMCH may be useful as functional food ingredients for protecting endothelial dysfunction or related disease.
No takes yet. Share an insight, caveat, or question.
Oh et al. (2019) studied H2O2-mediated oxidative injury in human umbilical vein endothelial cells (HUVECs). Blue mussel-α-chymotrypsin hydrolysate (BMCH) vs. H2O2 treatment alone was evaluated on HUVEC viability, ROS generation, and apoptosis. Pre-treatment with blue mussel-α-chymotrypsin hydrolysate (BMCH) increased HUVEC viability, reduced ROS generation, and decreased H2O2-mediated apoptosis through inhibition of caspase-3 activation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: